New Lupus Drug Drug to Generate $2 Billion in Annual Sales for GSK and HGSI
Pharmalot submits: Every so often, a new approval generates significant attention. And the FDA endorsement of Benlysta, the first new treatment for lupus in 56 years, is one of those moments. The injectable med, which will be marketed by Human Genome Sciences (HGSI) and GlaxoSmithKline (GSK), is forecast to generate at least $2 billion in annual sales thanks to a $35,000 price tag, despite cautionary language for certain patients. The med, which will actually about cost $40,000 in the first year, will become available later this month. There is no REMS requirement or Black Box warning, which heartened Wall Street. Nonetheless, insurance reimbursement remains somewhat fuzzy. Meanwhile, Human Genome Sciences agreed to conduct another clinical trial in African-American lupus patients. Here’s why… “As expected, the label states that black/African Americans benefitted less, writes Leerink Swann biotech analyst Joseph Schwartz in an investor note. He points out that the label states ‘although noComplete Story »
- Original article
- Login or register to post comments
